Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

News Daily News

Even Low-Dose Steroids Increase the Risk of CVD

Michael O'Riordan

December 03, 2020

News Conference News AHA 2020

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Todd Neale

November 16, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Caitlin E. Cox

October 21, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Daily News

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Yael L. Maxwell

September 14, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Michael O'Riordan

March 25, 2016

News Daily News

Diabetes Suele Pasar Desapercibida en Pacientes Hospitalizados con IAM

May 07, 2015

News Daily News

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

Advertisement

Even Low-Dose Steroids Increase the Risk of CVD

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Microvascular Disease Quadruples Risk of Leg Amputation

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Diabetes Suele Pasar Desapercibida en Pacientes Hospitalizados con IAM

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content